Scripps-eMed Covid-19 Study: A Prospective Monitoring Study for Those Individuals Treated With Paxlovid

Scripps Translational Science Institute917 enrolled

Overview

A prospective monitoring study for those individuals treated with Paxlovid

The purpose of this study is to understand the epidemiology and pathophysiology of Paxlovid rebound in patients with acute Covid-19 infection who have been prescribed the Paxlovid per standard of care. The study will be a collaborative effort between Scripps and eMed, digitally recruiting 800 participants who have tested positive for Covid-19 and have agreed to be prescribed Paxlovid on the eMed platform. The vision of the study is to understand Paxlovid rebound and ultimately inform management of acute Covid-19 infection.

Study Type

OBSERVATIONAL

Enrollment

917

Conditions

COVID-19

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 * Covid positive * Qualified for Paxlovid prescription (treatment decision already made prior to enrollment) Exclusion Criteria: * Non-english speaking * Resides outside of the United States

Locations (1)

Scripps Research Institute

San Diego, California, United States

Outcomes

Primary Outcomes

Paxlovid Rebound

Incidence of paxlovid rebound defined as test positivity after a documented negative rapid antigen test post 5 day course of Paxlovid

Time frame: 16 day period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.